Enovis (NYSE:ENOV) Trading Down 6.9% – Here’s Why

Enovis Corporation (NYSE:ENOV)’s share price traded down 6.9% during mid-day trading on Wednesday . The stock traded as low as $22.97 and last traded at $22.6160. 324,629 shares were traded during trading, a decline of 69% from the average session volume of 1,042,034 shares. The stock had previously closed at $24.28.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Needham & Company LLC raised their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company decreased their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a report on Sunday, May 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Finally, Zacks Research raised Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Enovis Stock Down 1.6%

The stock has a 50-day moving average of $24.04 and a two-hundred day moving average of $25.10. The company has a market cap of $1.30 billion, a P/E ratio of -1.14 and a beta of 1.41. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Enovis

A number of large investors have recently bought and sold shares of ENOV. California State Teachers Retirement System grew its stake in Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after purchasing an additional 621 shares during the last quarter. MGO One Seven LLC lifted its holdings in shares of Enovis by 9.4% in the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock valued at $202,000 after purchasing an additional 650 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Enovis by 0.4% in the 3rd quarter. Rhumbline Advisers now owns 173,023 shares of the company’s stock valued at $5,250,000 after purchasing an additional 682 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. Finally, Empowered Funds LLC increased its position in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.